UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): December 22, 2009
ORAMED
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
(State
or other jurisdiction
of
incorporation)
|
000-50298
(Commission
File Number)
|
98-0376008
(IRS
Employer
Identification
No.)
|
Hi-Tech
Park 2/5 Givat Ram
PO
Box 39098
Jerusalem,
Israel 91390
(Address
of principal executive offices and zip code)
Registrant’s
telephone number, including area code: 972-2-566-0001
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
ITEM
7.01
|
REGULATION
FD DISCLOSURE
|
On
December 21, 2009, Oramed Pharmaceuticals Inc. issued a press release announcing
that Dr. Roy Eldor will present an overview of the clinical development of
Oramed's Oral Insulin capsule at the first International Conference of the
Bildirici Center for Diabetes Care Research. The conference will be held at the
Wohl Center, Bar Ilan University, in Ramat Gan, Israel, on December 21-23, and
Dr. Eldor’s presentation will be given on December 22 at 4:10 PM. He will
highlight all of the clinical work that Oramed has competed to date, from
preclinical trials to its current Phase 2b trial that is underway. Dr. Eldor is
the principal investigator for all of Oramed’s clinical trials conducted at
Hadassah Medical Center. He is a physician in the Diabetes Unit and
Endocrinology Department of Hadassah Medical Center.
A copy of
the press release is attached to this Current Report on Form 8-K as Exhibit 99.1
and is incorporated by reference herein.
|
ITEM
9.01
|
FINANCIAL
STATEMENTS AND EXHIBITS.
|
|
(d)
|
Exhibits
|
|
Exhibit
Number
|
Description
|
|
|
99.1
|
Press
Release dated December 21,
2009.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ORAMED PHARMACEUTICALS
INC.
|
||||
|
Dated:
December 22, 2009
|
||||
|
By:
|
/s/
Nadav Kidron
|
|||
|
Nadav
Kidron
|
||||
|
President,
CEO and Director
|
||||
Exhibit
Index
|
Exhibit
Number
|
Description
|
|
|
99.1
|
Press
Release dated December 21,
2009.
|
Oramed’s
Dr. Roy Eldor was Chosen to Lecture at the First International
Conference
held by the Bildirici Center for Diabetes Care Research in Israel.
JERUSALEM,
Israel – December 21, 2009– Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB)
(http://www.oramed.com), a developer of alternative drug delivery systems,
announced today that Dr. Roy Eldor will present an overview of the clinical
development of Oramed's Oral Insulin capsule. Dr. Eldor is the
principal investigator for all of Oramed’s clinical trials conducted at Hadassah
Medical Center. He is a physician in the Diabetes Unit and Endocrinology
Department of Hadassah Medical Center.
The
conference will take place at the Wohl Center, Bar Ilan University, in Ramat
Gan, Israel, on December 21-23. Dr. Eldor’s presentation will be given on
December 22 at 4:10 PM. He will be highlighting all of the clinical work that
Oramed has completed to date, ranging from preclinical trials to its current
Phase 2b trial.
“Oramed
is honored to have been invited to present at this very important conference to
share the clinical development of its Oral Insulin Capsule with the scientific
community” says Dr. Roy Eldor.
About
the Conference:
The
Conference will start to focus on the translation of “cutting edge” diabetes
research into practical clinical care, with a particular emphasis on the
organization and delivery of care in different health systems. Updates and
overviews will be given by invited speakers from around the world, together with
workshop and debate sessions and submitted oral and poster
presentations.
For
More information, please visit www.diabetescenter.org.il
About
Oramed Pharmaceuticals
Oramed
Pharmaceuticals is a technology pioneer in the field of oral delivery solutions
for drugs and vaccines presently delivered via injection. Oramed is seeking
to revolutionize the treatment of diabetes through its patented flagship
product, an orally ingestible insulin capsule currently in phase 2 clinical
trials. Established in 2006, Oramed’s technology is based on over 25 years of
research by top research scientists at Jerusalem’s Hadassah Medical Center. The
Company’s corporate and R&D headquarters are based in
Jerusalem.
For more
information, please visit www.oramed.com.
Forward-looking
statements
Some of the statements contained in
this press release are forward-looking statements which involve known and
unknown risks, uncertainties and other factors which may cause the actual
results, performance or achievements of the company, or industry results, to be
materially different from any future results, performance or achievements
expressed or implied by such forward looking statements, including the risks and
uncertainties related to the progress, timing, cost, and results of clinical
trials and product development programs; difficulties or delays in obtaining
regulatory approval for our product candidates; competition from other
pharmaceutical or biotechnology companies; and the company’s ability to obtain
additional funding required to conduct its research, development and
commercialization activities. Please refer to the company’s filings with the
Securities and Exchange Commission for a comprehensive list of risk factors that
could cause actual results, performance or achievements of the company to differ
materially from those expressed or implied in such forward looking statements.
The company undertakes no obligation to update or revise any forward-looking
statements.
Company
and Investor Relations Contacts:
Oramed
Pharmaceuticals
Tara
Horn
USA: +1
646-240-4193
Int’l: +
972-54-334-318
Office: +
972-2-566-0001
Email: tara@oramed.com